RESUMEN
Endocannabinoids protect against seizures, but their mechanism of action is still unclear, as they can have effects independent of known cannabinoid receptors. Using Drosophila melanogaster, which lacks canonical cannabinoid receptors, we report that the endocannabinoids anandamide and 2-arachidonoylglycerol protect against seizures in multiple fly seizure models. Surprisingly, inhibition of anandamide catabolism renders flies insensitive to protection by anandamide, indicating that anandamide metabolites are responsible for seizure protection. Consistent with this finding, arachidonic acid, a direct metabolite of anandamide, protects against seizures. To identify downstream effectors, we test for a role of transient receptor potential (TRP) channels and find that the TRPV1 antagonist capsazepine blocks the protective effect of anandamide. Also, a targeted genetic screen of TRP channels identifies water witch as a mediator of protection by anandamide. Using a Drosophila model, we reveal the role of arachidonic acid in seizure protection and identify a cannabinoid-receptor-1/2-independent mechanism of endocannabinoid seizure protection.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Ácidos Araquidónicos/uso terapéutico , Proteínas de Drosophila/metabolismo , Endocannabinoides/uso terapéutico , Glicéridos/uso terapéutico , Convulsiones/prevención & control , Canales de Potencial de Receptor Transitorio/metabolismo , Animales , Ácidos Araquidónicos/metabolismo , Calcio/metabolismo , Modelos Animales de Enfermedad , Proteínas de Drosophila/deficiencia , Proteínas de Drosophila/genética , Drosophila melanogaster/metabolismo , Endocannabinoides/metabolismo , Alcamidas Poliinsaturadas/metabolismo , Alcamidas Poliinsaturadas/uso terapéutico , ARN Guía de Kinetoplastida/metabolismo , Receptor Cannabinoide CB1/metabolismo , Convulsiones/patología , Canales de Potencial de Receptor Transitorio/genéticaRESUMEN
Parkinson's disease (PD), the most common neurodegenerative movement disorder, is characterized by the progressive loss of dopaminergic neurons in substantia nigra. The underlying mechanisms of PD pathogenesis have not been fully illustrated and currently PD remains incurable. Accumulating evidences suggest that mitochondrial dysfunction plays pivotal role in the dopaminergic neuronal death. Therefore, discovery of novel and safe agent for rescuing mitochondrial dysfunction would benefit PD treatment. Here we demonstrated for the first time that α-Arbutin (Arb), a natural polyphenol extracted from Ericaceae species, displayed significant protective effect on the rotenone (Rot)-induced mitochondrial dysfunction and apoptosis of human neuroblastoma cell (SH-SY5Y). We further found that the neuroprotective effect of Arb was associated with ameliorating oxidative stress, stabilizing of mitochondrial membrane potential, and enhancing adenosine triphosphate production. To investigate the underlying mechanism, we checked the AMP-activated protein kinase and autophagy pathway and we found that both were involved in the neuroprotection of Arb. Moreover, we explored the protective effect of Arb in drosophila PD model and found that Arb rescued parkin deficiency-induced motor function disability and mitochondrial abnormality of drosophila. Taken together, our study demonstrated that Arb got excellent neuroprotective effect on PD models both in vitro and in vivo and Arb might serve as a potent therapeutic agent for the treatment of PD.
Asunto(s)
Antioxidantes/uso terapéutico , Arbutina/uso terapéutico , Ericaceae/química , Mitocondrias/efectos de los fármacos , Fármacos Neuroprotectores/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/química , Adenosina Trifosfato/biosíntesis , Adenilato Quinasa/metabolismo , Animales , Antioxidantes/aislamiento & purificación , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Arbutina/aislamiento & purificación , Arbutina/farmacología , Autofagia/efectos de los fármacos , Línea Celular Tumoral , Proteínas de Drosophila/deficiencia , Proteínas de Drosophila/genética , Drosophila melanogaster/efectos de los fármacos , Drosophila melanogaster/genética , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias/fisiología , Neuroblastoma/patología , Fármacos Neuroprotectores/aislamiento & purificación , Fármacos Neuroprotectores/farmacología , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Enfermedad de Parkinson/metabolismo , Trastornos Parkinsonianos/tratamiento farmacológico , Rotenona/toxicidad , Ubiquitina-Proteína Ligasas/deficiencia , Ubiquitina-Proteína Ligasas/genéticaRESUMEN
Since Drosophila melanogaster has proven to be a useful model system to study phenotypes of oncogenic mutations and to identify new anti-cancer drugs, we generated human BRAFV600E homologous dRaf mutant (dRafA572E ) Drosophila melanogaster strains to use these for characterisation of mutant phenotypes and exploit these phenotypes for drug testing. For mutant gene expression, the GAL4/UAS expression system was used. dRafA572E was expressed tissue-specific in the eye, epidermis, heart, wings, secretory glands and in the whole animal. Expression of dRaf A572E under the control of an eye-specific driver led to semi-lethality and a rough eye phenotype. The vast majority of other tissue-specific and ubiquitous drivers led to a lethal phenotype only. The rough eye phenotype was used to test BRAF inhibitor vemurafenib and MEK1/2 inhibitor cobimetinib. There was no phenotype rescue by this treatment. However, a significant rescue of the lethal phenotype was observed under a gut-specific driver. Here, MEK1/2 inhibitor cobimetinib rescued Drosophila larvae to reach pupal stage in 37% of cases as compared to 1% in control experiments. Taken together, the BRAFV600E homolog dRaf A572E exerts mostly lethal effects in Drosophila. Gut-specific dRaf A572E expression might in future be developed further for drug testing.
Asunto(s)
Azetidinas/farmacología , Proteínas de Drosophila/genética , Drosophila melanogaster/genética , Quinasas Quinasa Quinasa PAM/antagonistas & inhibidores , Piperidinas/farmacología , Proteínas Proto-Oncogénicas c-raf/genética , Animales , Proteínas de Drosophila/biosíntesis , Proteínas de Drosophila/deficiencia , Proteínas de Drosophila/fisiología , Evaluación Preclínica de Medicamentos , Regulación del Desarrollo de la Expresión Génica , Genes Letales , Intestinos/enzimología , Larva , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Especificidad de Órganos , Fenotipo , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas B-raf/fisiología , Proteínas Proto-Oncogénicas c-raf/biosíntesis , Proteínas Proto-Oncogénicas c-raf/deficiencia , Proteínas Proto-Oncogénicas c-raf/fisiología , Vemurafenib/farmacologíaRESUMEN
The common fruit fly Drosophila melanogaster (Dm) is a simple animal species that contributed significantly to the development of neurobiology whose leucine-rich repeat kinase 2 mutants (LRRK2) loss-of-function in the WD40 domain represent a very interesting tool to look into physiopathology of Parkinson's disease (PD). Accordingly, LRRK2 Dm have also the potential to contribute to reveal innovative therapeutic approaches to its treatment. Withania somnifera Dunal, a plant that grows spontaneously also in Mediterranean regions, is known in folk medicine for its anti-inflammatory and protective properties against neurodegeneration. The aim of this study was to evaluate the neuroprotective effects of its standardized root methanolic extract (Wse) on the LRRK2 loss-of-function Dm model of PD. To this end mutant and wild type (WT) flies were administered Wse, through diet, at different concentrations as larvae and adults (L+/A+) or as adults (L-/A+) only. LRRK2 mutants have a significantly reduced lifespan and compromised motor function and mitochondrial morphology compared to WT flies 1% Wse-enriched diet, administered to Dm LRRK2 as L-/A+and improved a) locomotor activity b) muscle electrophysiological response to stimuli and also c) protected against mitochondria degeneration. In contrast, the administration of Wse to Dm LRRK2 as L+/A+, no matter at which concentration, worsened lifespan and determined the appearance of increased endosomal activity in the thoracic ganglia. These results, while confirming that the LRRK2 loss-of-function in the WD40 domain represents a valid model of PD, reveal that under appropriate concentrations Wse can be usefully employed to counteract some deficits associated with the disease. However, a careful assessment of the risks, likely related to the impaired endosomal activity, is required.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Proteínas de Drosophila/deficiencia , Drosophila melanogaster/efectos de los fármacos , Trastornos Parkinsonianos/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/uso terapéutico , Proteínas Serina-Treonina Quinasas/deficiencia , Withania/química , Animales , Antiparkinsonianos/aislamiento & purificación , Antiparkinsonianos/farmacología , Antiparkinsonianos/toxicidad , Proteínas de Drosophila/genética , Drosophila melanogaster/crecimiento & desarrollo , Evaluación Preclínica de Medicamentos , Endosomas/efectos de los fármacos , Ganglios de Invertebrados/efectos de los fármacos , Ganglios de Invertebrados/ultraestructura , Larva , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina , Locomoción/efectos de los fármacos , Longevidad/efectos de los fármacos , Metanol , Mitocondrias/efectos de los fármacos , Mitocondrias/ultraestructura , Unión Neuromuscular/efectos de los fármacos , Unión Neuromuscular/fisiopatología , Trastornos Parkinsonianos/patología , Trastornos Parkinsonianos/fisiopatología , Extractos Vegetales/farmacología , Extractos Vegetales/toxicidad , Raíces de Plantas/química , Proteínas Serina-Treonina Quinasas/genética , Tiempo de Reacción/efectos de los fármacos , Método Simple Ciego , Potenciales Sinápticos/efectos de los fármacosRESUMEN
Classic galactosemia is a genetic disorder that results from profound loss of galactose-1P-uridylyltransferase (GALT). Affected infants experience a rapid escalation of potentially lethal acute symptoms following exposure to milk. Dietary restriction of galactose prevents or resolves the acute sequelae; however, many patients experience profound long-term complications. Despite decades of research, the mechanisms that underlie pathophysiology in classic galactosemia remain unclear. Recently, we developed a Drosophila melanogaster model of classic galactosemia and demonstrated that, like patients, GALT-null Drosophila succumb in development if exposed to galactose but live if maintained on a galactose-restricted diet. Prior models of experimental galactosemia have implicated a possible association between galactose exposure and oxidative stress. Here we describe application of our fly genetic model of galactosemia to the question of whether oxidative stress contributes to the acute galactose sensitivity of GALT-null animals. Our first approach tested the impact of pro- and antioxidant food supplements on the survival of GALT-null and control larvae. We observed a clear pattern: the oxidants paraquat and DMSO each had a negative impact on the survival of mutant but not control animals exposed to galactose, and the antioxidants vitamin C and α-mangostin each had the opposite effect. Biochemical markers also confirmed that galactose and paraquat synergistically increased oxidative stress on all cohorts tested but, interestingly, the mutant animals showed a decreased response relative to controls. Finally, we tested the expression levels of two transcripts responsive to oxidative stress, GSTD6 and GSTE7, in mutant and control larvae exposed to galactose and found that both genes were induced, one by more than 40-fold. Combined, these results implicate oxidative stress and response as contributing factors in the acute galactose sensitivity of GALT-null Drosophila and, by extension, suggest that reactive oxygen species might also contribute to the acute pathophysiology in classic galactosemia.
Asunto(s)
Galactosemias/genética , Galactosemias/metabolismo , Animales , Antioxidantes/farmacología , Ácido Ascórbico/farmacología , Cisteína/metabolismo , Dimetilsulfóxido/toxicidad , Modelos Animales de Enfermedad , Proteínas de Drosophila/deficiencia , Proteínas de Drosophila/genética , Proteínas de Drosophila/metabolismo , Drosophila melanogaster/efectos de los fármacos , Drosophila melanogaster/enzimología , Drosophila melanogaster/genética , Galactosa/metabolismo , Galactosa/toxicidad , Galactosemias/tratamiento farmacológico , Galactosemias/etiología , Galactosafosfatos/metabolismo , Expresión Génica/efectos de los fármacos , Técnicas de Inactivación de Genes , Genes de Insecto , Glutatión/metabolismo , Glutatión Transferasa/genética , Glutatión Transferasa/metabolismo , Humanos , Mutación , Estrés Oxidativo/efectos de los fármacos , Paraquat/toxicidad , Especies Reactivas de Oxígeno/metabolismo , UDP-Glucosa-Hexosa-1-Fosfato Uridiltransferasa/deficiencia , UDP-Glucosa-Hexosa-1-Fosfato Uridiltransferasa/genética , Xantonas/farmacologíaRESUMEN
Malvolio (Mvl) encodes the sole Drosophila melanogaster homologue of divalent metal transporter-1 (DMT1). The Drosophila transporter has been implicated in iron, manganese and copper cellular import. Indeed, the extent of metal specificity for this family of transporters is still under investigation in many eukaryotic species. Here, we revisit metal accumulation in Mvl mutants raised under normal and metal-supplemented diets. We found iron deficiency in Mvl mutant flies, whereas whole body copper and manganese concentrations remained unaltered. Iron supplementation restored total body iron concentrations in Mvl mutants, but without replenishing iron stores in the middle midgut, suggesting a role for Mvl in systemic iron trafficking, in addition to a role in intestinal iron absorption. Interestingly, dietary copper sulphate supplementation further exacerbated the iron deficiency. We investigated whether dietary copper affected iron storage through the function of an insect multicopper oxidase (MCO), because the mammalian MCO ceruloplasmin is known to regulate iron storage in the liver. We identified a Drosophila MCO mutant that suppressed aspects of the Mvl mutant phenotype and most notably Mvl, MCO3 double mutants showed normal intestinal iron storage. Therefore, MCO3 may encode an insect ferroxidase. Intriguingly, MCO3 mutants had a mild accumulation of copper, which was suppressed in Mvl mutants, revealing a reciprocal genetic interaction between the two genes.
Asunto(s)
Proteínas de Drosophila/deficiencia , Drosophila melanogaster/enzimología , Intestinos/enzimología , Bombas Iónicas/genética , Hierro/metabolismo , Mutación/genética , Oxidorreductasas/deficiencia , Secuencia de Aminoácidos , Animales , Dieta , Proteínas de Drosophila/química , Proteínas de Drosophila/genética , Proteínas de Drosophila/metabolismo , Bombas Iónicas/química , Bombas Iónicas/metabolismo , Datos de Secuencia Molecular , Oxidorreductasas/metabolismo , Alineación de SecuenciaRESUMEN
Despite considerable progress over recent years, the prognosis of invasive aspergillosis (IA) remains unfavorable, reflecting an incomplete understanding of Aspergillus pathogenesis and suboptimal antifungal efficacy in vivo. Mammalian host systems including rodents and rabbits are important tools in elucidating antifungal drug activity and the immunopathogenesis of IA. Nonetheless, they are hampered by limitations that impose a "bottleneck" in mass screening of novel antifungal compounds and putative Aspergillus virulence factors including their cost, labor intensity and ethical constraints. Drosophila melanogaster is an invertebrate host with a long tract record of genetic studies and a simple, yet highly conserved innate immune system. Herein, we describe our experience using this fly model as a facile, non-laborious, inexpensive pathosystem for high-throughput screening of novel antifungal compounds and putative Aspergillus mutants, and studying antifungal innate immunity. We present three infection protocols (i.e., injection, rolling, ingestion) that introduce Aspergillus either directly into the hemolymph or at different epithelial surfaces of Toll-deficient Drosophila flies. As a proof of principle, we demonstrate attenuated virulence of known hypovirulent Aspergillus strains and protection of Aspergillus-infected flies given oral Aspergillus-active agents such is voriconazole. These protocols can be adapted for similar studies of other fungal pathogens. Crossing and generation of Toll-deficient Drosophila flies takes 3 weeks; Aspergillus conidial preparation takes 3 days; fly inoculation depending on the infection assay takes 1 to 6-8 hours; and assessment of fly survival, Aspergillus strain virulence, Drosophila innate host parameters and/or drug activity takes 4-8 days.
Asunto(s)
Antifúngicos/farmacología , Aspergillus/efectos de los fármacos , Aspergillus/patogenicidad , Proteínas de Drosophila/genética , Drosophila melanogaster/microbiología , Receptores Toll-Like/genética , Animales , Proteínas de Drosophila/deficiencia , Drosophila melanogaster/genética , Drosophila melanogaster/inmunología , Ingestión de Alimentos , Eliminación de Gen , Ensayos Analíticos de Alto Rendimiento , Inyecciones , Pruebas de Sensibilidad Microbiana , Modelos Animales , Receptores Toll-Like/deficiencia , VirulenciaRESUMEN
The mechanisms underlying neuron death in Parkinson's disease are unknown, but both genetic defects and environmental factors are implicated in its pathogenesis. Mutations in the parkin gene lead to autosomal recessive juvenile Parkinsonism (AR-JP). Here we report that compared to control flies, Drosophila lacking parkin show significantly reduced lifespan but no difference in dopamine neuron numbers when raised on food supplemented with environmental pesticides or mitochondrial toxins. Moreover, chelation of redox-active metals, anti-oxidants and overexpression of superoxide dismutase 1 all significantly reversed the reduced longevity of parkin-deficient flies. Finally, parkin deficiency exacerbated the rough eye phenotype of Drosophila caused by overexpression of the copper importer B (Ctr1B). Taken together, our results demonstrate an important function of parkin in the protection against redox-active metals and pesticides implicated in the etiology of Parkinson's disease. They also corroborate that oxidative stress, perhaps as a consequence of mitochondrial dysfunction, is a major determinant of morbidity in parkin mutant flies.
Asunto(s)
Sistema Nervioso Central/metabolismo , Proteínas de Drosophila/deficiencia , Drosophila melanogaster/genética , Longevidad/genética , Mutación/genética , Neuronas/metabolismo , Ubiquitina-Proteína Ligasas/deficiencia , Animales , Sistema Nervioso Central/efectos de los fármacos , Modelos Animales de Enfermedad , Proteínas de Drosophila/genética , Longevidad/efectos de los fármacos , Neuronas/efectos de los fármacos , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/metabolismo , Ubiquitina-Proteína Ligasas/genéticaRESUMEN
Septic shock has an extremely high mortality rate, with approximately 200,000 people dying from sepsis annually in the U.S. The high mortality results in part from severe hypotension secondary to high serum NO concentrations. Reducing NO levels should be beneficial in sepsis, but NOS inhibitors have had a checkered history in animal models, and one such agent increased mortality in a clinical trial. An alternative approach to reduce NO levels in sepsis is to use an NO scavenger, which should leave sufficient free NO for normal physiological functions. Using a well-established model of bacterial sepsis in Drosophila melanogaster, we found that cobinamide, a B(12) analog and an effective NO scavenger in vitro, dramatically improved fly survival. Cobinamide augmented the effect of an antibiotic and was beneficial even in immune-deficient flies. Cobinamide's mechanism of action appeared to be from reducing NO levels and improving cardiac function.